Annual EBIT
-$165.74 M
-$8.20 M-5.20%
31 December 2023
Summary:
BioXcel Therapeutics annual earnings before interest & taxes is currently -$165.74 million, with the most recent change of -$8.20 million (-5.20%) on 31 December 2023. During the last 3 years, it has fallen by -$83.60 million (-101.77%). BTAI annual EBIT is now -7717.88% below its all-time high of -$2.12 million, reached on 31 December 2016.BTAI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$9.86 M
-$5.26 M-114.39%
30 September 2024
Summary:
BioXcel Therapeutics quarterly earnings before interest & taxes is currently -$9.86 million, with the most recent change of -$5.26 million (-114.39%) on 30 September 2024. Over the past year, it has increased by +$37.37 million (+79.13%). BTAI quarterly EBIT is now -1763.89% below its all-time high of -$529.00 thousand, reached on 31 March 2017.BTAI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$56.46 M
+$37.37 M+39.83%
30 September 2024
Summary:
BioXcel Therapeutics TTM earnings before interest & taxes is currently -$56.46 million, with the most recent change of +$37.37 million (+39.83%) on 30 September 2024. Over the past year, it has increased by +$142.34 million (+71.60%). BTAI TTM EBIT is now -10573.72% below its all-time high of -$529.00 thousand, reached on 31 March 2017.BTAI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BTAI EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.2% | +79.1% | +71.6% |
| 3 y3 years | -101.8% | +63.2% | +44.6% |
| 5 y5 years | -730.3% | -9.6% | -74.5% |
BTAI EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -101.8% | at low | -114.4% | +81.0% | at high | +71.6% |
| 5 y | 5 years | -730.3% | at low | -114.4% | +81.0% | -74.5% | +71.6% |
| alltime | all time | -7717.9% | at low | -1763.9% | +81.0% | <-9999.0% | +71.6% |
BioXcel Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.86 M(+114.4%) | -$56.46 M(-39.8%) |
| June 2024 | - | -$4.60 M(-80.2%) | -$93.84 M(-32.7%) |
| Mar 2024 | - | -$23.18 M(+23.2%) | -$139.50 M(-15.8%) |
| Dec 2023 | -$165.74 M(+5.2%) | -$18.82 M(-60.2%) | -$165.74 M(-16.6%) |
| Sept 2023 | - | -$47.23 M(-6.0%) | -$198.81 M(+4.8%) |
| June 2023 | - | -$50.26 M(+1.7%) | -$189.68 M(+8.1%) |
| Mar 2023 | - | -$49.43 M(-4.7%) | -$175.51 M(+11.4%) |
| Dec 2022 | -$157.54 M(+47.4%) | -$51.89 M(+36.2%) | -$157.54 M(+19.6%) |
| Sept 2022 | - | -$38.10 M(+5.6%) | -$131.74 M(+9.4%) |
| June 2022 | - | -$36.08 M(+14.7%) | -$120.45 M(+7.6%) |
| Mar 2022 | - | -$31.46 M(+20.6%) | -$111.97 M(+4.8%) |
| Dec 2021 | -$106.89 M(+30.1%) | -$26.09 M(-2.7%) | -$106.87 M(+4.9%) |
| Sept 2021 | - | -$26.81 M(-2.9%) | -$101.87 M(+2.1%) |
| June 2021 | - | -$27.60 M(+4.7%) | -$99.80 M(+6.6%) |
| Mar 2021 | - | -$26.37 M(+25.1%) | -$93.61 M(+14.0%) |
| Dec 2020 | -$82.14 M | -$21.08 M(-14.8%) | -$82.14 M(+18.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$24.75 M(+15.6%) | -$69.36 M(+29.4%) |
| June 2020 | - | -$21.41 M(+43.6%) | -$53.61 M(+31.3%) |
| Mar 2020 | - | -$14.90 M(+79.5%) | -$40.84 M(+22.4%) |
| Dec 2019 | -$32.95 M(+65.1%) | -$8.30 M(-7.8%) | -$33.36 M(+3.1%) |
| Sept 2019 | - | -$9.00 M(+4.2%) | -$32.37 M(+13.6%) |
| June 2019 | - | -$8.63 M(+16.4%) | -$28.49 M(+23.3%) |
| Mar 2019 | - | -$7.42 M(+1.4%) | -$23.09 M(+15.7%) |
| Dec 2018 | -$19.96 M(+340.0%) | -$7.31 M(+42.9%) | -$19.96 M(+31.5%) |
| Sept 2018 | - | -$5.12 M(+57.8%) | -$15.18 M(+38.3%) |
| June 2018 | - | -$3.24 M(-24.3%) | -$10.97 M(+32.3%) |
| Mar 2018 | - | -$4.29 M(+69.7%) | -$8.29 M(+82.8%) |
| Dec 2017 | -$4.54 M(+114.0%) | -$2.53 M(+175.5%) | -$4.54 M(+125.6%) |
| Sept 2017 | - | -$917.00 K(+62.3%) | -$2.01 M(+83.8%) |
| June 2017 | - | -$565.00 K(+6.8%) | -$1.09 M(+106.8%) |
| Mar 2017 | - | -$529.00 K | -$529.00 K |
| Dec 2016 | -$2.12 M | - | - |
FAQ
- What is BioXcel Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual EBIT year-on-year change?
- What is BioXcel Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly EBIT year-on-year change?
- What is BioXcel Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for BioXcel Therapeutics?
- What is BioXcel Therapeutics TTM EBIT year-on-year change?
What is BioXcel Therapeutics annual earnings before interest & taxes?
The current annual EBIT of BTAI is -$165.74 M
What is the all time high annual EBIT for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual earnings before interest & taxes is -$2.12 M
What is BioXcel Therapeutics annual EBIT year-on-year change?
Over the past year, BTAI annual earnings before interest & taxes has changed by -$8.20 M (-5.20%)
What is BioXcel Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of BTAI is -$9.86 M
What is the all time high quarterly EBIT for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly earnings before interest & taxes is -$529.00 K
What is BioXcel Therapeutics quarterly EBIT year-on-year change?
Over the past year, BTAI quarterly earnings before interest & taxes has changed by +$37.37 M (+79.13%)
What is BioXcel Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of BTAI is -$56.46 M
What is the all time high TTM EBIT for BioXcel Therapeutics?
BioXcel Therapeutics all-time high TTM earnings before interest & taxes is -$529.00 K
What is BioXcel Therapeutics TTM EBIT year-on-year change?
Over the past year, BTAI TTM earnings before interest & taxes has changed by +$142.34 M (+71.60%)